Author: Ravi Shankar

Revenues for the first nine months of 2026;
Excellent commercial performance;
Objectives confirmed for 2026

• 9M 2026 revenue: 570.1 million euros
• 80 orders received, including 71 for new LNG carriers: second-best commercial performance
• Order book of 299 units valued at 1.8 billion euros for the core business
• Strong innovation drive and presentation of GTT Energy’s new services offering
• 2026 objectives confirmed despite an uncertain geopolitical context

Paris – October 23, 2026. GTT, the technological expert in membrane containment systems used to transport and store liquefied gases, today announces its revenue for the first nine months of 2026.

Commenting on the results, François Michel, Chief Executive Officer of GTT, said:

“The Group’s commercial performance during the first nine months of 2026 demonstrates the strength of the LNG market’s fundamentals: new final investment decisions have been taken for a total of 51 Mtpa, in addition to the 84 Mtpa signed in 2025, attesting to the fact that there is sustainable demand for LNG. The 80 orders recorded also provide us with very strong visibility for the coming years. We are maintaining a close dialogue with our customers and partners regarding the ongoing uncertainty caused by the current conflict in the Middle East.

Our strategy of innovation and value proposition strengthening has been illustrated with the announcement of numerous innovations at Gastech in Bangkok in September. In particular, we presented our new services offering: the LNG Performance Centre. Built for LNG industry stakeholders, this platform is designed to support ship-owners and charterers in optimising the performance of their LNG carrier fleets and managing their cargo. The deployment of Cargo Insights, the first module of this offering, marks a major milestone and demonstrates our ability to respond quickly to our customers’ and partners’ expectations.

Our new GTT Marine division continued its commercial development and the contracts signed with leading players underline the relevance of our integrated offering, which combines data collection equipment with digital solutions for performance monitoring and improvement.

Revenues for the first nine months of 2026 are down by -4.9% compared to last year’s record revenues level. The Group’s activity for the first nine month of 2026 mainly reflects the lower number of LNG carriers under construction, linked to the low level of order intake registered during the first nine months of 2025. Moreover, the recent trend towards earlier ship delivery dates appears to be reversing, with delivery dates realigning with initial contractual milestones, resulting in a slight shift, representing less than 2% of the nine months revenue.

Furthermore, the Group is dedicating additional resources to develop its new Services activities, in addition to the investments dedicated to its Digital offering, in line with its strategy.

Taking into account these elements, the Group confirms its objectives for 2026 despite an uncertain geopolitical context.

Over the long run, the Group should benefit from the significant number of Final Investments Decisions taken for new liquefaction plants, the current strong order intake trend and the very high orderbook level, which provides high visibility for several years.”  

Group business activity in the first nine months of 2026

• GTT Energy: strong business activity characterized by diversified and significant orders

As of September 30, 2026, the Group recorded a total of 80 orders, including 71 orders for new LNG carriers with deliveries expected between 2028 and 2030. To be noted in the orders included in the second quarter of 2026: two additional 177,000 m³ LNG carriers¹ featuring a three-tank configuration. During the period, the Group also announced two orders for four LNG carriers, each with a capacity of 200,000 m³, incorporating Mark III Flex+ technology.

GTT was also selected to design the cryogenic tanks for two VLECs (Very Large Ethane Carriers). Deliveries are scheduled between the fourth quarter of 2028 and the first quarter of 2029.

Business activity over the first nine months of 2026 was notably marked by the numerous orders received for infrastructure linked to the Liquefied Natural Gas (LNG) sector.
The Group has won several orders for the design of onshore storage tanks, including three LNG tanks with capacities of 240,000 m³ and one ethane tank with a capacity of 200,000 m³. Built in China, they will be the largest tanks in the world equipped with GTT’s GST^® technology. Their delivery is expected to be between the fourth quarter of 2027 and the fourth quarter of 2028.
The Group also booked an order for a new FSRU² with a capacity of 170,000 m³, and was selected to design the tanks for the first FLNG³ in the United States. With the largest production capacity in the world, this FLNG will be built as part of the Delfin FLNG 1 project. The delivery of these units is scheduled for the first quarter of 2029 (FSRU) and mid-2030 (FLNG).

Over the first nine months of 2026, 66 LNG carriers were delivered, as well as two VLECs and one FSRU.

As of September 30, 2026, GTT Energy’s revenues stood at 522 million euros. Revenues fell by 9.4% compared with 9M 2025, due to a lower number of new LNG carriers under construction during the period.

• GTT Marine: continued development of products and services and first commercial successes enabled by the new integrated offering

The GTT Marine division continued its growth trajectory whilst pursuing the development of its integrated platform and implementing its new organisational structure.

During the period, several contracts were won to equip container ships with Shaft Power Meters (SPM) and onboard performance solutions designed and distributed by GTT Marine. Activities relating to Voyage Data Recorders (VDR) and Electronic Fuel Monitoring Systems (EFMS) have maintained their growth momentum. Notably, new contracts were won for EFMS following the granting of accreditations by oil majors in the first quarter of 2026.

The commercial synergies expected from the creation of GTT Marine are gradually materializing, thanks to its integrated offering combining hardware and software. The contracts concluded with Petrobras and Petronas in the first half of the year, as well as the contract signed with a Greek ship-owner in the third quarter of 2026 to equip its entire fleet with data collection equipment relating to performance monitoring and route optimisation solutions, highlight how the Group’s offering, which was presented at the Posidonia conference in Athens in June 2026, is meeting customers’ expectations.

As of September 30, 2026, GTT Marine revenues fully benefited from the integration of Danelec and reached 47.4 million euros.

• Innovation: recognized technological advances and a major milestone reached in the development of GTT Energy’s services offering

The Group maintained a sustained level of research and innovation activity during the first nine months of 2026.

At Gastech 2026 in Bangkok, GTT teams presented several new developments aimed at optimising the performance of LNG carriers, which have been recognised by classification societies.

GTT obtained an Approval in Principle by Lloyd’s Register to increase the interval between two dry-dockings for LNG carriers equipped with GTT membrane containment systems to 7.5 years, rather than the usual 5 years. Extending the maintenance interval could increase vessel availability while reducing maintenance requirements and lowering the associated costs, without compromising on safety and reliability standards. In addition, the confirmation by GTT and Lloyd’s Register Advisory of the compatibility of the 200,000 m³ LNG carriers with the majority of existing LNG terminals, along with the launch of a joint development project between GTT, Shell and Lloyd’s Register for a 200,000 m³ LNG carrier concept combining hybrid-electric propulsion with GTT NEXT1^® cargo containment technology, confirm the relevance of the new designs proposed by the Group to its customers and partners.

The adoption of the new configurations developed and offered by GTT was also illustrated by the first orders for three-tank LNG carriers during the period. By optimising the ratio of LNG cargo volume to insulation surface area, the design improves vessels’ thermal efficiency and reduces the LNG boil-off gas rate⁴ without compromising on performance or operational flexibility. In addition, in LNG infrastructure, the three onshore LNG storage tanks with a capacity of 240,000 m³ and the ethane storage tank with a capacity of 200,000 m³ to be built in China demonstrate the Group’s ability to adapt its offerings in line with evolving market needs and integrate increasingly complex project requirements.

GTT reached a major milestone in September 2026 with the launch of the LNG Performance Centre, a new services ecosystem designed to support ship-owners and charterers in optimising the performance of their LNG carrier fleets and managing their cargo. GTT’s integrated approach is based on three pillars: cargo management, voyage optimisation and containment system performance monitoring. This offering will combined advice from experts and seasoned captains, available 24/7, with a suite of digital solutions underpinned by GTT’s proprietary data and advanced models. At Gastech 2026, GTT Energy teams presented the first module of the LNG Performance Centre, Cargo Insights, which is dedicated to real-time cargo monitoring.

• Conflict in the Middle East

The ongoing conflict in the Middle East continues to disrupt the energy and maritime transportation markets⁵, notably the persisting uncertainties related to the navigation possibility in the Strait of Hormuz. In the short-term, the Group believes that these disruptions are having a limited impact on its business, in particular on ship delivery dates, which are realigning with initial contractual milestones, after being brought forward in previous months. Over the long run, should these disruptions continue, their adverse effects should remain limited, given the strong fundamentals of the LNG market.

Order book at September 30, 2026

As of January 1, 2026, GTT’s order book, excluding LNG as fuel, comprised 288 units. The following developments have occurred since January 1:

• Deliveries completed: 66 LNG carriers, 2 VLECs, 1 FSRU;
• Orders received: 71 LNG carriers, 2 ethane carriers, 5 onshore storage tanks, 1 FSRU, 1 FLNG;

As of September 30, 2026, the order book, excluding LNG as fuel, stood at 299 units, broken down as follows:

• 266 LNG carriers;
• 21 ethane carriers;
• 3 FSRUs;
• 4 FLNGs;
• 5 onshore storage tanks.

Regarding LNG as fuel, with the delivery of 8 vessels, there were 40 vessels in the order book at September 30, 2026.

 

Change in consolidated revenues for the first nine months of 2026

(in millions of euros)	9M 2025	9M 2026	Change
Total revenues	599.6	570.1	-4.9%
GTT Energy	576.0	522.0	-9.4%
Containment systems	558.3	505.5	-9.5%
of which LNG carriers/ethane carriers	528.1	467.9	-11.4%
of which FSRUs6	6.6	12.1	+83.6%
of which FLNGs7	7.3	8.8	+21.4%
of which onshore storage tanks	–	–	–
of which LNG-powered vessels	16.4	16.7	+1.5%
Services to operations	17.7	16.4	-7%
GTT Marine	19.9	47.4	138.2%
Hydrogen (Elogen)	3.7	0.7	-82.1%

Consolidated revenues for the first nine months of 2026 were 570.1 million euros, down 4.9% compared with the first nine months of 2025. This is in line with the lower number of LNG carriers under construction linked and the low level of orders recorded during the first nine months of 2025.

• Revenues related to the construction of containment systems stood at 505.5 million euros. They include:
  • Royalties from LNG and ethane carriers, which amounted to 467.9 million euros (-11.4% vs 9M 2025), reflecting the drop in the number of LNG carriers under construction.
  • Royalties from the construction of FSRUs and FLNGs, showing an increase of +83.6% and +21.4%, respectively, linked to the increased volume of units under construction compared with the first nine months of 2025.
  • Royalties generated by the LNG as fuel business, totalling 16.7 million euros (+1.5%).
• Revenue from services to operations were down 7% (16.4 million euros at 9M 2026 vs 17.7 million euros at 9M 2025) primarily due to the slowdown in the certification business. This was partially offset by the slight increase in assistance services and engineering studies.
• Marine and digital solutions revenues reached 47.4 million euros at September 30, 2026 (+138.2% vs 9M 2025) driven by the contribution of Danelec and the Safety business, which is dedicated to safety equipment and performance data collection. The GTT Marine division therefore contributes 8% of the Group’s revenues.

• Revenues from the designing and manufacturing of electrolysers (Elogen) stood at 0.7 million euros, reflecting the refocusing of its activities on research and development.

 

•  

Outlook

GTT recalls its targets for the 2026 fiscal year, namely:

• 2026 consolidated revenues between 740 and 780 million euros,
• Consolidated EBITDA for 2026 between 490 and 530 million euros,
• Dividend policy maintained⁸.

Regarding the outlook for the current year, the Group notes that ship delivery dates, instead of being ahead of schedule like observed in past few months, appear to be reversing, with delivery dates realigning with initial contractual milestones. Furthermore, the Group is dedicating additional resources to develop its new Services activities, in addition to the investments dedicated to its Digital offering, in line with its strategy.
In light of the above, the Group confirms its objectives for 2026 despite an uncertain geopolitical context.

Over the long term, the Group should benefit from the significant number of Final Investments Decisions signed for new liquefaction capacities, the current strong order momentum and the very high orderbook level, which provides high visibility for several years.

 

***

First nine months of 2026 activity update presentation

François Michel, Chief Executive Officer, and Thierry Hochoa, Chief Financial Officer, will comment on GTT’s activity during the first nine months of 2026 and answer questions from the financial community during a conference call to be held, in English, on Friday, October 23, 2026, at 6:15 p.m. Paris time.

This conference will be broadcast live on GTT’s website.

To join the conference call, please dial one of the following numbers five to ten minutes before the start of the conference:

• France: +33 1 70 91 87 04
• United Kingdom: +44 1 212 818 004
• United States: +1 718 705 87 96
• Other countries: +39 02 802 09 11

Confirmation code: 140215

The presentation document will be available on the website on October 23 at 6:15 p.m.

Financial calendar

• Publication of 2026 annual results: February 24, 2027 (after close of trading)
• 2027 first-quarter activity update: April 22, 2027 (after close of trading)
• Shareholders’ Meeting: June 16, 2027
• Publication of 2027 half-year results: July 28, 2027 (after close of trading)

 

About GTT

GTT is a technology and engineering group with expertise in the design and development of cryogenic membrane containment systems for use in the transport and storage of liquefied gases. Over the past 60 years, the GTT Group has designed and developed, to the highest standards of excellence, some of the most innovative technologies used in LNG carriers, floating terminals, onshore storage tanks and multi-gas carriers. As part of its commitment to building a sustainable world, GTT develops new solutions designed to support ship-owners and energy providers in their journey towards a decarbonised future. As such, the Group offers systems designed to enable commercial vessels to use LNG as fuel, develops cutting-edge marine and digital solutions to enhance vessels’ economic and environmental performance, and actively pursues innovation in the field of low-carbon solutions.

GTT is listed on Euronext Paris, Compartment A (ISIN FR0011726835 Euronext Paris: GTT) and is notably included in the CAC Next 20, SBF 120, Stoxx Europe 600 and MSCI Small Cap indices.

Investor Relations Contact:
Information-financiere@gtt.frinformation-financiere@gtt.fr / +33 (0)1 30 23 42 64 / +33 (0)1 30 23 20 87
Press Contacts:
communication@gtt.fr / +33 (0)1 30 23 56 37
For more information, visit www.gtt.fr.

Important notice

The figures presented here are those customarily used and communicated to the markets by GTT. This message includes forward-looking information and statements. Such statements include financial projections and estimates, the assumptions on which they are based, as well as statements about projects, objectives and expectations regarding future operations, profits or services, or future performance. Although GTT management believes that these forward-looking statements are reasonable, investors and GTT shareholders should be aware that such forward-looking information and statements are subject to many risks and uncertainties that are generally difficult to predict and beyond the control of GTT, and may cause results and developments to differ significantly from those expressed, implied or predicted in the forward-looking statements or information. Such risks include those explained or identified in the public documents filed by GTT with the French Financial Markets Authority (AMF – Autorité des Marchés Financiers), including those listed in the “Risk Factors” section of the GTT Universal Registration Document filed with the AMF on April 27, 2026, and the half-year financial report released on July 28, 2026. Investors and GTT shareholders should note that if some or all of these risks are realised they may have a significant unfavourable impact on GTT.

---

¹ Two vessels ordered in November 2025 and two additional vessels ordered in May 2026

² Floating Storage Regasification Unit

³ Floating Liquefied Natural Gas vessel

⁴ An approximate 6% reduction compared with a four-tank configuration equipped with the same technology

⁵ The outbreak of the conflict led to the temporary closure of several liquefied natural gas production and export facilities in Qatar and the United Arab Emirates, one of which was partially damaged in Qatar (two liquefaction trains representing a total of 13 Mtpa of production capacity).

⁶ Floating Storage Regasification Units.

⁷ Floating Liquefied Natural Gas vessels.

⁸ Subject to approval by the Shareholders’ Meeting and the amount of distributable net income in the GTT S.A. corporate financial statements.

Attachment

• GTT – Q3 2026 Activity Update – Press Release

Company Announcement

COPENHAGEN, Denmark; October 23, 2026

• Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S^®) compared to investigator’s choice chemotherapy
• Results demonstrated statistically significant and clinically meaningful improvement in PFS and OS in patients with platinum-resistant ovarian cancer (PROC)
• Data will be submitted for presentation at a future medical meeting and discussed with regulatory authorities worldwide

Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S^®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), in patients with platinum-resistant ovarian cancer (PROC) regardless of FRα expression level or prior treatment with mirvetuximab. The trial met its primary endpoint of progression-free survival (PFS), with Rina-S demonstrating a statistically significant and clinically meaningful improvement compared with investigator’s choice chemotherapy in the intent-to-treat (ITT) and in the primary analysis set (PAS) populations.

The ITT population (N=584) comprised of all randomized patients with PROC, regardless of FRα expression. The PAS population (N=492) mandated patients with FRα expression ≥75% PS2+ to have been treated with mirvetuximab.

In the ITT population, Rina-S demonstrated a 71% reduction in the risk of disease progression or death (HR 0.29; 95% CI, 0.23-0.37; p<0.0001). In the PAS population, Rina-S demonstrated a 67% reduction in the risk of disease progression or death (HR 0.33; 95% CI, 0.26–0.42; p<0.0001).

The study also met its key secondary endpoint of overall survival (OS), demonstrating a statically significant and clinically meaningful improvement in the ITT population (HR 0.43; 95% CI, 0.31–0.59; p<0.0001) and in the PAS population (HR 0.44; 95% CI, 0.31–0.63; p<0.0001).

The observed safety profile was consistent with the known profile of Rina-S, with no new safety signals or unexpected safety concerns identified.

“As the first Phase 3 readout from our Rina-S program, the positive topline results from RAINFOL-02 mark a significant milestone for Genmab and strengthen our confidence in Rina-S’s potential for patients with platinum-resistant ovarian cancer. These results advance our ambition to become a leader in gynecologic oncology and reflect our commitment to improving the lives of patients with high unmet medical needs,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “We look forward to discussing these results and potential next steps with regulatory authorities worldwide. We are deeply grateful to the patients, caregivers, and investigators whose participation made this study possible.”

Based on these results, Genmab plans to engage with regulatory authorities worldwide regarding potential next steps. The data will also be submitted for presentation at a future medical meeting.

“Platinum-resistant ovarian cancer remains one of the greatest challenges in gynecologic oncology, with patients often facing a poor prognosis and limited effective treatment options. The Phase 3 RAINFOL-02 results set a new benchmark in addressing this urgent unmet need regardless of FRα expression,” said Angeles Alvarez Secord, MD, MHSc, the study’s lead investigator for the Gynecologic Oncology Group (GOG) and Professor of Obstetrics and Gynecology at the Duke Cancer Institute. “The 71% reduction in the risk of disease progression and 57% reduction in the risk of death underscore the potential of Rina-S to change clinical practice if approved by offering a therapeutic option for a broad patient population.”

Rina-S is being evaluated in a broad clinical development program spanning multiple gynecologic cancers and other solid tumors. The program includes five Phase 3 trials evaluating Rina-S in PROC (RAINFOL-02; NCT06619236), recurrent or progressive endometrial cancer (RAINFOL-03; NCT07166094), platinum-sensitive ovarian cancer (PSOC) maintenance therapy (RAINFOL-04; NCT07225270), second-line PSOC (RAINFOL-07; NCT07564141), and in first-line ovarian cancer as maintenance therapy (RAINFOL-10; NCT07859215). Additional studies include the Phase 1/2 RAINFOL-01 trial (NCT05579366) and Phase 2 trials in non-small cell lung cancer (RAINFOL-05; NCT07288177) and advanced gastrointestinal cancers (RAINFOL-09; NCT07539311).

On Wednesday, October 28 at 5:00 p.m. CET/12:00 p.m. EDT, Genmab will host an investor update. To register, visit genmab.com/events-presentations.

About the RAINFOL-02 Trial
RAINFOL-02 (NCT06619236) is a randomized, open-label, multicenter Phase 3 study evaluating the efficacy and safety of Rina-S versus investigator’s choice chemotherapy in 582 patients with PROC regardless of FRα expression level. Patients are randomized 1:1 to receive either Rina-S 120 mg/m² on Day 1 of each three-week treatment cycle or one of four standard-of-care chemotherapy agents: paclitaxel, topotecan, PLD, or gemcitabine. The primary endpoint is investigator-assessed PFS. Key secondary endpoints are OS and objective response rate (ORR). Other secondary endpoints include PFS by blinded independent central review, duration of response, incidence of adverse events and laboratory abnormalities, time from randomization to second disease progression or death, and change from baseline in global health status/quality of life. Efficacy is evaluated in two populations. The ITT population (N = 584) includes all randomized patients, regardless of FRα expression level. The PAS (N=492), a subset of the ITT population, includes only patients with FRα expression <75% PS2+ and patients previously treated with mirvetuximab if eligible based on FRα expression ≥75% PS2+ and available in the region.

About Ovarian Cancer
Ovarian cancer (OC) is a major global health issue, more than 320,000 new cases diagnosed annually worldwide.ⁱ It ranks as the eighth most common cancer and the eighth leading cause of cancer-related deaths among women globally.ⁱⁱ The disease is often diagnosed at an advanced stage because its symptoms, including abdominal bloating, pelvic pain and difficulty eating, can be subtle and nonspecific.ⁱⁱⁱ Approximately 70-90% of women with advanced-stage OC worldwide experience a recurrence after initial treatment.^iv OC has a low five-year survival rate, which varies significantly by region, but generally hovers around 30-50%.^v,vi

About Rinatabart Sesutecan (Rina-S; GEN1184)
Rina-S (GEN1184) is an investigational ADC. It is composed of a novel human monoclonal antibody directed at FRα, a hydrophilic protease-cleavable linker, and exatecan, a TOPO1 inhibitor payload. The clinical trial program for Rina-S continues to expand, including ovarian, endometrial, and other cancers with unmet need.

The safety and efficacy of Rina-S have not been established. Please visit https://clinicaltrials.gov/ for more information.

About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, ADCs, immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn, X, Facebook and Instagram.

Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^®; HuMax^®; DuoBody^®; HexaBody^®; DuoHexaBody^®, HexElect^®, KYSO^® and RAINFOL™; Rina-S^® is a trademark of ProfoundBio, US, Co. and Genmab (Suzhou) Co., Ltd.

---

ⁱ World Cancer Research Fund International. https://www.wcrf.org/cancer-trends/ovarian-cancer-statistics/. Accessed Oct 2025.
ⁱⁱ World Ovarian Cancer Coalition. https://worldovariancancercoalition.org/about-ovarian-cancer/key-stats/. Accessed Oct 2025.
ⁱⁱⁱ Dilley, James et al. Ovarian cancer symptoms, routes to diagnosis and survival – Population cohort study in the ‘no screen’ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecologic oncology vol. 158,2 (2020): 316-322. doi:10.1016/j.ygyno.2020.05.002.
^iv Ovarian Cancer Research Alliance. https://ocrahope.org/patients/diagnosis-and-treatment/recurrence/
^v European Institute of Women’s Health. https://eurohealth.ie/policy‐brief‐women‐and‐ovarian‐cancer‐in‐the‐eu‐2018/. Accessed Oct 2025.
^vi American Cancer Society. Stages of Ovarian Cancer. https://www.cancer.org/cancer/types/ovarian-cancer/detection-diagnosis-staging/survival-rates.html. Accessed Oct 2025.

Company Announcement no. 43
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Attachment

• 2310266_CA43_RAINFOL-02

Company Announcement

COPENHAGEN, Denmark; October 23, 2026

• Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S^®) compared to investigator’s choice chemotherapy
• Results demonstrated statistically significant and clinically meaningful improvement in PFS and OS in patients with platinum-resistant ovarian cancer (PROC)
• Data will be submitted for presentation at a future medical meeting and discussed with regulatory authorities worldwide

Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S^®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), in patients with platinum-resistant ovarian cancer (PROC) regardless of FRα expression level or prior treatment with mirvetuximab. The trial met its primary endpoint of progression-free survival (PFS), with Rina-S demonstrating a statistically significant and clinically meaningful improvement compared with investigator’s choice chemotherapy in the intent-to-treat (ITT) and in the primary analysis set (PAS) populations.

The ITT population (N=584) comprised of all randomized patients with PROC, regardless of FRα expression. The PAS population (N=492) mandated patients with FRα expression ≥75% PS2+ to have been treated with mirvetuximab.

In the ITT population, Rina-S demonstrated a 71% reduction in the risk of disease progression or death (HR 0.29; 95% CI, 0.23-0.37; p<0.0001). In the PAS population, Rina-S demonstrated a 67% reduction in the risk of disease progression or death (HR 0.33; 95% CI, 0.26–0.42; p<0.0001).

The study also met its key secondary endpoint of overall survival (OS), demonstrating a statically significant and clinically meaningful improvement in the ITT population (HR 0.43; 95% CI, 0.31–0.59; p<0.0001) and in the PAS population (HR 0.44; 95% CI, 0.31–0.63; p<0.0001).

The observed safety profile was consistent with the known profile of Rina-S, with no new safety signals or unexpected safety concerns identified.

“As the first Phase 3 readout from our Rina-S program, the positive topline results from RAINFOL-02 mark a significant milestone for Genmab and strengthen our confidence in Rina-S’s potential for patients with platinum-resistant ovarian cancer. These results advance our ambition to become a leader in gynecologic oncology and reflect our commitment to improving the lives of patients with high unmet medical needs,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “We look forward to discussing these results and potential next steps with regulatory authorities worldwide. We are deeply grateful to the patients, caregivers, and investigators whose participation made this study possible.”

Based on these results, Genmab plans to engage with regulatory authorities worldwide regarding potential next steps. The data will also be submitted for presentation at a future medical meeting.

“Platinum-resistant ovarian cancer remains one of the greatest challenges in gynecologic oncology, with patients often facing a poor prognosis and limited effective treatment options. The Phase 3 RAINFOL-02 results set a new benchmark in addressing this urgent unmet need regardless of FRα expression,” said Angeles Alvarez Secord, MD, MHSc, the study’s lead investigator for the Gynecologic Oncology Group (GOG) and Professor of Obstetrics and Gynecology at the Duke Cancer Institute. “The 71% reduction in the risk of disease progression and 57% reduction in the risk of death underscore the potential of Rina-S to change clinical practice if approved by offering a therapeutic option for a broad patient population.”

Rina-S is being evaluated in a broad clinical development program spanning multiple gynecologic cancers and other solid tumors. The program includes five Phase 3 trials evaluating Rina-S in PROC (RAINFOL-02; NCT06619236), recurrent or progressive endometrial cancer (RAINFOL-03; NCT07166094), platinum-sensitive ovarian cancer (PSOC) maintenance therapy (RAINFOL-04; NCT07225270), second-line PSOC (RAINFOL-07; NCT07564141), and in first-line ovarian cancer as maintenance therapy (RAINFOL-10; NCT07859215). Additional studies include the Phase 1/2 RAINFOL-01 trial (NCT05579366) and Phase 2 trials in non-small cell lung cancer (RAINFOL-05; NCT07288177) and advanced gastrointestinal cancers (RAINFOL-09; NCT07539311).

On Wednesday, October 28 at 5:00 p.m. CET/12:00 p.m. EDT, Genmab will host an investor update. To register, visit genmab.com/events-presentations.

About the RAINFOL-02 Trial
RAINFOL-02 (NCT06619236) is a randomized, open-label, multicenter Phase 3 study evaluating the efficacy and safety of Rina-S versus investigator’s choice chemotherapy in 582 patients with PROC regardless of FRα expression level. Patients are randomized 1:1 to receive either Rina-S 120 mg/m² on Day 1 of each three-week treatment cycle or one of four standard-of-care chemotherapy agents: paclitaxel, topotecan, PLD, or gemcitabine. The primary endpoint is investigator-assessed PFS. Key secondary endpoints are OS and objective response rate (ORR). Other secondary endpoints include PFS by blinded independent central review, duration of response, incidence of adverse events and laboratory abnormalities, time from randomization to second disease progression or death, and change from baseline in global health status/quality of life. Efficacy is evaluated in two populations. The ITT population (N = 584) includes all randomized patients, regardless of FRα expression level. The PAS (N=492), a subset of the ITT population, includes only patients with FRα expression <75% PS2+ and patients previously treated with mirvetuximab if eligible based on FRα expression ≥75% PS2+ and available in the region.

About Ovarian Cancer
Ovarian cancer (OC) is a major global health issue, more than 320,000 new cases diagnosed annually worldwide.ⁱ It ranks as the eighth most common cancer and the eighth leading cause of cancer-related deaths among women globally.ⁱⁱ The disease is often diagnosed at an advanced stage because its symptoms, including abdominal bloating, pelvic pain and difficulty eating, can be subtle and nonspecific.ⁱⁱⁱ Approximately 70-90% of women with advanced-stage OC worldwide experience a recurrence after initial treatment.^iv OC has a low five-year survival rate, which varies significantly by region, but generally hovers around 30-50%.^v,vi

About Rinatabart Sesutecan (Rina-S; GEN1184)
Rina-S (GEN1184) is an investigational ADC. It is composed of a novel human monoclonal antibody directed at FRα, a hydrophilic protease-cleavable linker, and exatecan, a TOPO1 inhibitor payload. The clinical trial program for Rina-S continues to expand, including ovarian, endometrial, and other cancers with unmet need.

The safety and efficacy of Rina-S have not been established. Please visit https://clinicaltrials.gov/ for more information.

About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, ADCs, immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn, X, Facebook and Instagram.

Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^®; HuMax^®; DuoBody^®; HexaBody^®; DuoHexaBody^®, HexElect^®, KYSO^® and RAINFOL™; Rina-S^® is a trademark of ProfoundBio, US, Co. and Genmab (Suzhou) Co., Ltd.

---

ⁱ World Cancer Research Fund International. https://www.wcrf.org/cancer-trends/ovarian-cancer-statistics/. Accessed Oct 2025.
ⁱⁱ World Ovarian Cancer Coalition. https://worldovariancancercoalition.org/about-ovarian-cancer/key-stats/. Accessed Oct 2025.
ⁱⁱⁱ Dilley, James et al. Ovarian cancer symptoms, routes to diagnosis and survival – Population cohort study in the ‘no screen’ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecologic oncology vol. 158,2 (2020): 316-322. doi:10.1016/j.ygyno.2020.05.002.
^iv Ovarian Cancer Research Alliance. https://ocrahope.org/patients/diagnosis-and-treatment/recurrence/
^v European Institute of Women’s Health. https://eurohealth.ie/policy‐brief‐women‐and‐ovarian‐cancer‐in‐the‐eu‐2018/. Accessed Oct 2025.
^vi American Cancer Society. Stages of Ovarian Cancer. https://www.cancer.org/cancer/types/ovarian-cancer/detection-diagnosis-staging/survival-rates.html. Accessed Oct 2025.

Company Announcement no. 43
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Attachment

• 2310266_CA43_RAINFOL-02

GTT announces the appointment of Ms. Catherine Ronge as Chairwoman of its Board of Directors

Paris, October 23, 2026 – The Board of Directors of GTT, meeting today, decided to appoint Ms. Catherine Ronge, currently Chairwoman of the Nominations and Compensation Committee, as Chairwoman of the Board of Directors, succeeding Mr. Philippe Berterottière, who has decided to resign from his duties on the Board of Directors, effective November 16, 2026.

Mr. Philippe Berterottière’s departure from the Board marks, in respect with the highest standards of corporate governance, the completion of the successful transition period with Mr. François Michel, who joined the Group as Chief Executive Officer in January 2026.

The appointment of Ms. Catherine Ronge, in line with the succession plan established by the Board of Directors, reflects the Group’s determination to continue implementing its strategy. It demonstrates the Board’s confidence in her leadership, her deep knowledge of the Group, and her ability to support GTT’s ambitions in innovation, growth, and value creation.

Ms. Catherine Ronge has served as an independent director of the Board since 2021, Chairwoman of the Nominations and Compensation Committee since 2023, and a member of the Strategy & CSR Committee since 2021. She brings recognised expertise gained throughout a distinguished career within French organisations operating on an international scale.

Following these changes, GTT’s Board of Directors will comprise eight members, including seven independent directors (88%) and 50% women. The recruitment process for an additional independent director is currently underway.

Following this appointment, the composition of the Board committees will also evolve. Ms. Sandra Lagumina will succeed Ms. Catherine Ronge as Chairwoman of the Nominations and Compensation Committee and will step down from the Audit and Risk Committee. Moreover, Mr. Luc Gillet will join the Nominations and Compensation Committee, replacing Mr. Pierre Guiollot.

Philippe Berterottière commented: “After seventeen years at the helm of GTT, I believe the time has come for me to step down. I do so with great confidence in the future of a Group that has never been stronger, that is in very capable hands, and that possesses every asset needed to continue its development. Having supported François Michel since the beginning of this year on taking up his position as Chief Executive Officer, I consider that this transition has been successfully completed. Today, I am stepping down as Chair of the Board of Directors, and I am delighted with the Board’s decision to appoint Catherine Ronge, who knows the Group extremely well, having served on the Board since 2021 and chaired the Nominations and Compensation Committee since 2023.

Over these seventeen years, GTT has undergone a profound transformation and achieved a remarkable trajectory of growth and value creation. We have continuously innovated to respond to changing market dynamics, strengthened our technological leadership, expanded our network of industrial partners around the world and, above all, placed service to ship-owners at the very heart of our corporate culture. This unwavering commitment, combined with our capacity for innovation and the strength of our business model, has been the driving force behind sustained performance, as notably reflected in the Group’s share price performance.

I am proud of the journey we have undertaken and of the value created over the years for our customers, partners and shareholders. I would like to extend my warmest thanks to all the women and men of GTT who, through their talent, commitment and innovative spirit, have made possible this exceptional collective success. Today, I hand over the reins convinced that GTT has the talented people, the technology and the ambition required to sustain this momentum and reach new milestones in its development.”

François Michel, Chief Executive Officer of GTT, stated: “I would like to thank Philippe Berterottière for supporting me as I took up my position and for the close partnership we have built over the past several months. His knowledge of the LNG market and the maritime industry, together with his strategic vision, allowed me to gain a deeper understanding of GTT’s characteristics and of our customers’ and partners’ expectations. Under his leadership, GTT has become a world-class group, renowned for the excellence of its technology and the commitment of its teams. The Group’s new organisation around two divisions, Energy and Marine, as well as the development of new services, fully align with this momentum. Over the past months, I have worked closely with Catherine Ronge through the Board and the Nominations and Compensation Committee, and I look forward to working alongside her in her new role as Chairwoman of the Board. Her experience, her deep knowledge of GTT, and her understanding of economic, technological and societal challenges will be a significant asset to the Group’s governance.”

Catherine Ronge stated: “I would like to thank the directors for their confidence, and I fully appreciate the responsibility entrusted to me. It is a great honour to succeed Philippe Berterottière, who has elevated GTT’s operational and financial performance to outstanding levels. During his tenure, the Group achieved exceptional profitable and sustainable growth. He successfully attracted and mobilised talents throughout the organisation, making GTT a benchmark among French companies. Together with the Executive Management team, I will ensure that the Board of Directors continues to support GTT’s development in the best interests of its shareholders, employees, customers and all its stakeholders.”

Ms. Catherine Ronge biography

A former student of the École Normale Supérieure of Paris-Saclay and with a PhD in quantum physics, Catherine Ronge also graduated from a short executive programme at INSEAD. She began her career in 1984 as a research engineer at the CEA, then held various positions within the Air Liquide group (1988 to 1999) in the field of marketing, sales, strategy/M&A and R&D of the group as Vice-Chairperson.

Within the Suez group (1999 to 2006), she was Deputy Chief Executive Officer of Degrémont in charge of global industrial activities and of the North America subsidiary, then Chairwoman and Chief Executive Officer of Ondeo Industrial Solutions, a company bringing together all of the Suez Group’s engineering, construction, equipment manufacturing and industrial water operations worldwide.

She was the founding Chairwoman of the strategy, innovation and sustainable development consulting firm Weave Air (2006 to 2020).

Ms. Ronge was Chairwoman and Chief Executive Officer of the Le Garrec & Cie group, a family intermediate size business with diversified activities since June 2026. She is also a Director of Colas (since 2014) and non-voting board member at Paprec.

Following these changes:  

Composition of the Board of Directors

• Catherine Ronge (Chairwoman and independent director)
• Domitille Doat Le Bigot (independent director)
• Carolle Foissaud (independent director)
• Luc Gillet (independent director)
• Pierre Guiollot (director)
• Sandra Lagumina (independent director)
• Pascal Macioce (independent director)
• Antoine Rostand (independent director)

Composition of Committees

Nominations and Compensation Committee

• Sandra Lagumina (Chairwoman)
• Carolle Foissaud
• Luc Gillet 

Audit and Risks Committee

• Pascal Macioce (Chairman)
• Domitille Doat-Le Bigot
• Antoine Rostand 

Strategic and CSR Committee

• Antoine Rostand (Chairman)
• Catherine Ronge
• Luc Gillet

About GTT

GTT is a technology and engineering group with expertise in the design and development of cryogenic membrane containment systems for use in the transport and storage of liquefied gases. Over the past 60 years, the GTT Group has designed and developed, to the highest standards of excellence, some of the most innovative technologies used in LNG carriers, floating terminals, onshore storage tanks and multi-gas carriers. As part of its commitment to building a sustainable world, GTT develops new solutions designed to support ship-owners and energy providers in their journey towards a decarbonised future. As such, the Group offers systems designed to enable commercial vessels to use LNG as fuel, develops cutting-edge digital solutions to enhance vessels’ economic and environmental performance, and actively pursues innovation in the field of low-carbon solutions.

GTT is listed on Euronext Paris, Compartment A (ISIN FR0011726835 Euronext Paris: GTT) and is notably included in the CAC Next 20, SBF 120, Stoxx Europe 600 and MSCI Small Cap indices.

For more information, visit www.gtt.fr

Investor relations contact information-financiere@gtt.fr / +33 (0)1 30 23 42 64 / +33 (0)1 30 23 20 87

Media contact: communication@gtt.fr / +33 (0)1 30 23 56 37

Attachment

• PR_23102026_GTT announces the appointment of Ms. Catherine Ronge as Chairwoman of its Board of Directors

GTT announces the appointment of Ms. Catherine Ronge as Chairwoman of its Board of Directors

Paris, October 23, 2026 – The Board of Directors of GTT, meeting today, decided to appoint Ms. Catherine Ronge, currently Chairwoman of the Nominations and Compensation Committee, as Chairwoman of the Board of Directors, succeeding Mr. Philippe Berterottière, who has decided to resign from his duties on the Board of Directors, effective November 16, 2026.

Mr. Philippe Berterottière’s departure from the Board marks, in respect with the highest standards of corporate governance, the completion of the successful transition period with Mr. François Michel, who joined the Group as Chief Executive Officer in January 2026.

The appointment of Ms. Catherine Ronge, in line with the succession plan established by the Board of Directors, reflects the Group’s determination to continue implementing its strategy. It demonstrates the Board’s confidence in her leadership, her deep knowledge of the Group, and her ability to support GTT’s ambitions in innovation, growth, and value creation.

Ms. Catherine Ronge has served as an independent director of the Board since 2021, Chairwoman of the Nominations and Compensation Committee since 2023, and a member of the Strategy & CSR Committee since 2021. She brings recognised expertise gained throughout a distinguished career within French organisations operating on an international scale.

Following these changes, GTT’s Board of Directors will comprise eight members, including seven independent directors (88%) and 50% women. The recruitment process for an additional independent director is currently underway.

Following this appointment, the composition of the Board committees will also evolve. Ms. Sandra Lagumina will succeed Ms. Catherine Ronge as Chairwoman of the Nominations and Compensation Committee and will step down from the Audit and Risk Committee. Moreover, Mr. Luc Gillet will join the Nominations and Compensation Committee, replacing Mr. Pierre Guiollot.

Philippe Berterottière commented: “After seventeen years at the helm of GTT, I believe the time has come for me to step down. I do so with great confidence in the future of a Group that has never been stronger, that is in very capable hands, and that possesses every asset needed to continue its development. Having supported François Michel since the beginning of this year on taking up his position as Chief Executive Officer, I consider that this transition has been successfully completed. Today, I am stepping down as Chair of the Board of Directors, and I am delighted with the Board’s decision to appoint Catherine Ronge, who knows the Group extremely well, having served on the Board since 2021 and chaired the Nominations and Compensation Committee since 2023.

Over these seventeen years, GTT has undergone a profound transformation and achieved a remarkable trajectory of growth and value creation. We have continuously innovated to respond to changing market dynamics, strengthened our technological leadership, expanded our network of industrial partners around the world and, above all, placed service to ship-owners at the very heart of our corporate culture. This unwavering commitment, combined with our capacity for innovation and the strength of our business model, has been the driving force behind sustained performance, as notably reflected in the Group’s share price performance.

I am proud of the journey we have undertaken and of the value created over the years for our customers, partners and shareholders. I would like to extend my warmest thanks to all the women and men of GTT who, through their talent, commitment and innovative spirit, have made possible this exceptional collective success. Today, I hand over the reins convinced that GTT has the talented people, the technology and the ambition required to sustain this momentum and reach new milestones in its development.”

François Michel, Chief Executive Officer of GTT, stated: “I would like to thank Philippe Berterottière for supporting me as I took up my position and for the close partnership we have built over the past several months. His knowledge of the LNG market and the maritime industry, together with his strategic vision, allowed me to gain a deeper understanding of GTT’s characteristics and of our customers’ and partners’ expectations. Under his leadership, GTT has become a world-class group, renowned for the excellence of its technology and the commitment of its teams. The Group’s new organisation around two divisions, Energy and Marine, as well as the development of new services, fully align with this momentum. Over the past months, I have worked closely with Catherine Ronge through the Board and the Nominations and Compensation Committee, and I look forward to working alongside her in her new role as Chairwoman of the Board. Her experience, her deep knowledge of GTT, and her understanding of economic, technological and societal challenges will be a significant asset to the Group’s governance.”

Catherine Ronge stated: “I would like to thank the directors for their confidence, and I fully appreciate the responsibility entrusted to me. It is a great honour to succeed Philippe Berterottière, who has elevated GTT’s operational and financial performance to outstanding levels. During his tenure, the Group achieved exceptional profitable and sustainable growth. He successfully attracted and mobilised talents throughout the organisation, making GTT a benchmark among French companies. Together with the Executive Management team, I will ensure that the Board of Directors continues to support GTT’s development in the best interests of its shareholders, employees, customers and all its stakeholders.”

Ms. Catherine Ronge biography

A former student of the École Normale Supérieure of Paris-Saclay and with a PhD in quantum physics, Catherine Ronge also graduated from a short executive programme at INSEAD. She began her career in 1984 as a research engineer at the CEA, then held various positions within the Air Liquide group (1988 to 1999) in the field of marketing, sales, strategy/M&A and R&D of the group as Vice-Chairperson.

Within the Suez group (1999 to 2006), she was Deputy Chief Executive Officer of Degrémont in charge of global industrial activities and of the North America subsidiary, then Chairwoman and Chief Executive Officer of Ondeo Industrial Solutions, a company bringing together all of the Suez Group’s engineering, construction, equipment manufacturing and industrial water operations worldwide.

She was the founding Chairwoman of the strategy, innovation and sustainable development consulting firm Weave Air (2006 to 2020).

Ms. Ronge was Chairwoman and Chief Executive Officer of the Le Garrec & Cie group, a family intermediate size business with diversified activities since June 2026. She is also a Director of Colas (since 2014) and non-voting board member at Paprec.

Following these changes:  

Composition of the Board of Directors

• Catherine Ronge (Chairwoman and independent director)
• Domitille Doat Le Bigot (independent director)
• Carolle Foissaud (independent director)
• Luc Gillet (independent director)
• Pierre Guiollot (director)
• Sandra Lagumina (independent director)
• Pascal Macioce (independent director)
• Antoine Rostand (independent director)

Composition of Committees

Nominations and Compensation Committee

• Sandra Lagumina (Chairwoman)
• Carolle Foissaud
• Luc Gillet 

Audit and Risks Committee

• Pascal Macioce (Chairman)
• Domitille Doat-Le Bigot
• Antoine Rostand 

Strategic and CSR Committee

• Antoine Rostand (Chairman)
• Catherine Ronge
• Luc Gillet

About GTT

GTT is a technology and engineering group with expertise in the design and development of cryogenic membrane containment systems for use in the transport and storage of liquefied gases. Over the past 60 years, the GTT Group has designed and developed, to the highest standards of excellence, some of the most innovative technologies used in LNG carriers, floating terminals, onshore storage tanks and multi-gas carriers. As part of its commitment to building a sustainable world, GTT develops new solutions designed to support ship-owners and energy providers in their journey towards a decarbonised future. As such, the Group offers systems designed to enable commercial vessels to use LNG as fuel, develops cutting-edge digital solutions to enhance vessels’ economic and environmental performance, and actively pursues innovation in the field of low-carbon solutions.

GTT is listed on Euronext Paris, Compartment A (ISIN FR0011726835 Euronext Paris: GTT) and is notably included in the CAC Next 20, SBF 120, Stoxx Europe 600 and MSCI Small Cap indices.

For more information, visit www.gtt.fr

Investor relations contact information-financiere@gtt.fr / +33 (0)1 30 23 42 64 / +33 (0)1 30 23 20 87

Media contact: communication@gtt.fr / +33 (0)1 30 23 56 37

Attachment

• PR_23102026_GTT announces the appointment of Ms. Catherine Ronge as Chairwoman of its Board of Directors

GUELPH, Ontario, Oct. 23, 2026 (GLOBE NEWSWIRE) — Hammond Power Solutions Inc. (“HPS” or the “Company”) (TSX: HPS.A) today announced that it will release its financial results for the Third Quarter ended September 26, 2026, on Thursday, October 29, 2026, after markets close. Following the release of its financial results, HPS will hold a conference call and webcast on Friday, October 30, 2026, at 9:00 a.m. Eastern Time.

This call can be accessed by registration through participant links:

Date/Time:   October 30, 2026/ 9 a.m. ET

Live Call Participant Registration Link:
https://register-conf.media-server.com/register/BIcbe70ee5ce7e4659b749ece6d8a222b9

Audio-Only Webcast:
https://edge.media-server.com/mmc/p/bjuig9gc

A webcast replay will be available for 12 months.

ABOUT HAMMOND POWER SOLUTIONS INC.

Hammond Power Solutions Inc. (“HPS” or the “Company”) enables electrification through its broad range of dry-type transformers, power quality products, related magnetics and power conversion systems. HPS’ standard and custom-designed products are essential and ubiquitous in electrical distribution networks through an extensive range of end-user applications. The Company has manufacturing plants in North America, Europe and Asia and sells its products around the globe. HPS shares are listed on the Toronto Stock Exchange and trade under the symbol HPS.A.

Hammond Power Solutions – Energizing Our World

For further information, please contact:
David Feick
Investor Relations (519) 822-2441
ir@hammondpowersolutions.com   

GUELPH, Ontario, Oct. 23, 2026 (GLOBE NEWSWIRE) — Hammond Power Solutions Inc. (“HPS” or the “Company”) (TSX: HPS.A) today announced that it will release its financial results for the Third Quarter ended September 26, 2026, on Thursday, October 29, 2026, after markets close. Following the release of its financial results, HPS will hold a conference call and webcast on Friday, October 30, 2026, at 9:00 a.m. Eastern Time.

This call can be accessed by registration through participant links:

Date/Time:   October 30, 2026/ 9 a.m. ET

Live Call Participant Registration Link:
https://register-conf.media-server.com/register/BIcbe70ee5ce7e4659b749ece6d8a222b9

Audio-Only Webcast:
https://edge.media-server.com/mmc/p/bjuig9gc

A webcast replay will be available for 12 months.

ABOUT HAMMOND POWER SOLUTIONS INC.

Hammond Power Solutions Inc. (“HPS” or the “Company”) enables electrification through its broad range of dry-type transformers, power quality products, related magnetics and power conversion systems. HPS’ standard and custom-designed products are essential and ubiquitous in electrical distribution networks through an extensive range of end-user applications. The Company has manufacturing plants in North America, Europe and Asia and sells its products around the globe. HPS shares are listed on the Toronto Stock Exchange and trade under the symbol HPS.A.

Hammond Power Solutions – Energizing Our World

For further information, please contact:
David Feick
Investor Relations (519) 822-2441
ir@hammondpowersolutions.com   

  Financial information for the third quarter of 2026                                                                            Le 23 octobre 2026             

Revenue (at constant scope and exchange rates):

+53% in the third quarter of 2026

+21% in the first nine months of 2026

Revenue for the third quarter of 2026 

At constant scope and exchange rates, Group revenue for the third quarter of 2026 totaled 936 million euros, up 53%:

• Bolloré Energy: 851 million euros, +61%, resulting from the general increase in oil product prices and a 9% decrease in volumes sold, attributable in part to this increase;
• Industry: 76 million euros, +4%, thanks to growth in Systems activity, driven by Automatics System’s businesses, and despite a decrease in Blue activity;
• Other activities: 9 million euros, stable, reflecting an improvement in real estate revenue. On a gross basis, revenue was down by -17 million euros following the exit of the equity interest in Ovrsea from the scope of consolidation in December 2025 following its merger with Fusalpes.

On a reported basis, revenue increased by 49% compared with the third quarter of 2025, taking into account a -17 million euro change in the scope, primarily due to the exit of Ovrsea.

Revenue for the first nine months of 2026

At constant scope and exchange rates, revenue at the end of September 2026 was up by 21% to 2,580 million euros. Compared with the first nine months of 2025, the main sectors trended as follows:

• Bolloré Energy: 2,318 million euros, +24%, up amid a general context of increasing prices linked to the conflict in the Middle East, and despite a decline in volumes sold (-11%);
• Industry: 232 million euros, +2%, up slightly compared with the first nine months of 2025, driven by growth in Films (higher volumes and prices in dielectric films and packaging) and Systems activities, and despite a decline in Blue activities, mainly Bluebus;
• Other activities: 30 million euros, -4%, reflecting a decrease in real estate revenue. On a gross basis, revenue was down by -51 million euros following the exit of the equity interest in Ovrsea from the scope of consolidation in December 2025 following its merger with Fusalpes.

On a reported basis, revenue for the first nine months of the year increased by 19%, taking into account a  -48 million euro change in the scope, primarily due to the exit of Ovrsea.

Change in revenue by business activity

(in millions of euros)	Q3				9-month total
	2026	2025	Reported growth	Organic growth		2026	2025	Reported growth	Organic growth
Bolloré Energy	851	530	+60%	+61%		2,318	1,867	+24%	+24%
Industry	76	73	+4%	+4%		232	229	+1%	+2%
Others (Agricultural Assets, Holding and others)	9	27	-65%	–		30	81	-63%	-4%
Total	936	630	+49%	+53%		2,580	2,177	+19%	+21%

Highlights and recent events 

Compagnie de l’Odet

• Since the beginning of 2026, Compagnie de l’Odet has acquired 114 million Bolloré SE shares at a unit price of 4.39 euros (representing 4.1% of the share capital), for a total amount of 502 million euros, including 15 million shares held by subsidiaries of Bolloré SE, for 81 million euros, as part of the simplification of the Group’s structure.

Bluebus/Blue Solutions

• On September 8, Bolloré SE announced a proposal to discontinue the production of Bluebus electric buses, which may lead to the loss of 74 jobs. In a French market that has been less dynamic than expected, marked by intense competition and significant pricing pressure, Bluebus is not large enough to compete with other players in the sector. After years of actively searching for solutions and despite the efforts made to adapt its business model, the company determined that the necessary conditions were no longer present. An offer has been made by a European industrial company to acquire certain assets, allowing the social cost to be minimized.
• Bolloré SE also announced that it was proposing to refocus Blue Solutions’ strategy on 4^th generation batteries, which could lead to the loss of 41 jobs.

Vivendi demerger: Decision of the Paris Court of Appeal of July 8, 2026

In a ruling handed down on July 8, 2026, the Paris Court of Appeal, sitting as an extended bench, dismissed all of CIAM Fund’s claims. The Court held that Vivendi SE could not be regarded as being controlled by Bolloré SE within the meaning of subsections 3° and 4°of Article L. 233-3 I, of the French Commercial Code, and that the existence of control through concerted action, within the meaning of Section III of the same article, was likewise not established. CIAM Fund was ordered to pay a total of 350,000 euros under Article 700 of the French Code of Civil Procedure (Code de procédure civile), including 200,000 euros to Bolloré SE. CIAM Fund filed an appeal to the Court of Cassation on July 27, 2026.

Exceptional interim dividends

Following the distribution of an exceptional dividend of 4.2 billion euros by Bolloré SE in June 2026, Compagnie de l’Odet paid an exceptional interim dividend of 2.5 billion euros on September 29, 2026. On the same day, the companies that directly and indirectly control Compagnie de l’Odet (Sofibol, Financière V and Omnium Bolloré) also paid out exceptional interim dividends corresponding to the majority of the interim dividend amount received.

As a result of these exceptional interim dividend payments, Bolloré SE and its subsidiaries received a total amount of approximately 2 billion euros. These subsidiaries include Compagnie du Cambodge, Financière Moncey, and Société Industrielle et Financière de l’Artois. These three companies approved the payment of exceptional interim dividends of 13 euros per share for Compagnie du Cambodge (i.e. 789 million euros), 14 euros per share for Financière Moncey (i.e. 261 million euros), and 650 euros per share for Société Industrielle et Financière de l’Artois (i.e. 173 million euros), paid out on October 7, 2026.

Change in revenue by quarter

(in millions of euros)	Q1			Q2			Q3
	2026	2025 organic	2025	2026	2025 organic	2025	2026	2025 organic	2025
Bolloré Energy	731	678	675	736	663	661	851	530	530
Industry	74	77	78	82	78	78	76	73	73
Others (Agricultural Assets, Holding and others)	10	11	28	11	10	26	9	9	27
Total	815	766	782	829	751	765	936	613	630

All amounts are expressed in millions of euros and rounded to the nearest decimal.
As a result, the sum of the rounded amounts may differ slightly from the reported total.

Attachment

• 2026 10 23 Odet CAT3 _EN

Daridorexant, a dual orexin receptor antagonist, is the first investigational treatment in its class to demonstrate positive results in pediatric insomnia disorder, an area in which significant unmet needs remain for children and their families.  

A single 50 mg dose increased sleep time by 50 minutes overall and 64 minutes in children with neurodevelopmental disorders, moving participants closer to their recommended age‑appropriate sleep duration. 

Daridorexant was well tolerated across doses including 50 mg, the highest recommended dose for adults, with a pediatric safety profile consistent with the established adult evidence 

Sixteen presentations showcased the breadth of daridorexant research across adult clinical trials, real-world evidence and investigator-initiated studies in diverse populations with insomnia 

Allschwil, Switzerland – October 23, 2026 

Idorsia Ltd (SIX: IDIA) today announced results from the first and only Phase 2 study with a dual orexin receptor antagonist in children with insomnia disorder, presented to the scientific community at Sleep Europe 2026. Daridorexant featured prominently throughout the congress, with 16 Idorsia-sponsored and investigator-initiated presentations spanning pediatric and adult clinical research, real-world evidence, diverse populations with insomnia and changes in prescribing practice. 

Professor Carmen M. Schröder, MD, PhD, Department of Child and Adolescent Psychiatry, Strasbourg University Hospitals, commented: 

“This is the first controlled clinical study to show that a dual orexin receptor antagonist, with the right pharmacokinetic profile, can rapidly and meaningfully increase sleep duration in children and adolescents with insomnia disorder, without causing morning sleepiness. The clear dose-response and the consistency of the findings across objective and subjective sleep measures warrant further investigation in a Phase 3 study. While total sleep time improved in the overall children population, the results in children with neurodevelopmental disorders are particularly important, because insomnia worsens their core symptoms and comorbidities, while treatment options remain limited.” 

Marked efficacy of daridorexant in children with insomnia

In pediatric age, insomnia disorder causes persistent night-time symptoms and significant daytime impairment for children and their families, yet treatment options remain limited, with no approved pharmacotherapies in the US. 

The randomized, double-blind, placebo-controlled Phase 2 study (NCT05423717, Abstract) evaluated treatment with daridorexant 10, 25 and 50 mg, or placebo, over two weeks in 165 children and adolescents aged 10 to under 18 years with DSM-5 insomnia disorder. More than half of the participants had a diagnosed or subthreshold neurodevelopmental disorder, including autism spectrum disorder and/or attention-deficit/hyperactivity disorder. 

The study met its primary endpoint, demonstrating a statistically significant dose-response in objectively measured total sleep time after the first dose.  

A single dose of daridorexant 50 mg increased objective total sleep time by 50 minutes from baseline, compared with 20 minutes with placebo (least-square mean). In children and adolescents with neurodevelopmental disorders, daridorexant 50 mg increased objective total sleep time by 64 minutes from baseline, compared with 27 minutes with placebo (least-square mean). After two weeks, in the overall population, caregiver-reported total sleep time increased from baseline by approximately 69 minutes with daridorexant 50 mg, compared with approximately 30 minutes with placebo (least-square mean). 

Daridorexant 50 mg also provided the highest and most consistent improvements across measures of sleep initiation, sleep maintenance, and sleep quality while numerically reducing morning sleepiness. 

Daridorexant was well tolerated across all doses studied. At 50 mg, the highest recommended adult dose, the incidence of adverse events was similar to placebo, and the safety profile was consistent with the known adult safety profile. No adverse events suggestive of abuse potential or physical dependence and no withdrawal symptoms were observed. 

Professor Carmen M. Schröder concluded: 

“The efficacy findings are compelling, and the favorable safety and tolerability results add to our confidence in taking the next steps. The highest recommended adult dose was studied in children, including those with lower body weight, with no new safety findings observed. This provides a strong foundation for the future development of daridorexant in pediatric populations” 

Amer Joseph, MD, CMO and Head Global Clinical Development & Medical Affairs, commented: 

“Once again, the properties that we designed into daridorexant – rapid absorption, rapid elimination, and a relatively short terminal half-life – have proven to provide efficacy through the night without negatively impacting the next morning. In fact, the safety measures show an improvement in next- morning alertness. The compelling results in children with insomnia and ADHD and/or ASD as well as in children without neurodevelopmental disorders allow us to target a broad and underserved pediatric population. As the only DORA being investigated in children, daridorexant could become not only the sole drug recommended by the ESRS guideline for short and long-term treatment of insomnia in adults, but also a first-in-class treatment for the pediatric population.”  

Next steps in pediatric insomnia 

The manuscript describing the full dataset is currently under evaluation with a high-ranked scientific journal. In parallel, the team is consolidating supportive comments from global health authorities on the protocol for the pediatric Phase 3 clinical development program. The company expects to initiate the new program in the second half of next year. 

Presentation replay 

A recording of Professor Carmen Schröder’s presentation, featuring the same scientific content presented at Sleep Europe 2026, is available here: Watch the presentation 

An expanding evidence base in adults 

Beyond the pioneering pediatric study, 15 additional presentations demonstrated the growing breadth of evidence for daridorexant in adults. Across controlled clinical studies and routine clinical practice, improvements were observed in objective and subjective sleep measures, insomnia severity and daytime functioning, including in adults with psychiatric, neurological and neurodevelopmental comorbidities. 

In adults with insomnia and objectively measured short sleep duration, three months of continuous daridorexant 50 mg treatment improved sleep onset, sleep maintenance and total sleep time, based on both objective and subjective measures. 

Investigator-initiated research further reported improvement of sleep with daridorexant in menopausal women with insomnia and in patients with insomnia and epilepsy, major depressive disorder or sedative-hypnotic use disorder. 

The growing real-world evidence also showed improvements beyond the night. Prospective and retrospective studies reported reductions in insomnia severity alongside improvements in depressive symptoms, quality of life, and work productivity. 

Finally, a separate analysis of prescribing patterns across six countries found that increased DORA use coincided with reductions in benzodiazepine and Z-drug use, two classes of drugs associated with public safety concern. The overall volume of insomnia medication was not changed. 

Dieter Kunz, M.D., Director of the Sleep Research and Clinical Chronobiology Research Group at Charité – Universitätsmedizin Berlin, commented: 

“The research presented at Sleep Europe demonstrates both the breadth and maturity of the evidence for daridorexant. Across controlled studies and routine clinical practice, improvements were observed in objective and subjective sleep, insomnia severity and daytime functioning, including in patients with complex psychiatric, neurological and neurodevelopmental comorbidities. These findings show that the benefits established in the pivotal program are increasingly being observed in the diverse patients we treat in everyday practice. At the same time, prescribing data suggest that when DORAs are accessible, clinical practice can move away from traditional hypnotics, which are symptomatic only, towards a more disease-modifying-type of treatment for insomnia disorder.” 

An exploratory study in adults with ADHD and insomnia reported improvements in insomnia symptoms and sleep parameters in nearly two-thirds of patients after four weeks of daridorexant treatment, alongside improvements in measures of attention, mood, and anxiety.  

Giacomo Grassi, M.D., Ph.D., psychiatrist and researcher at Brain Center Firenze, commented: 

“A growing number of real-world studies show that the efficacy of daridorexant observed in clinical trials is also seen in the complex clinical populations we treat every day. This is particularly relevant for adults with ADHD, in whom sleep problems are the rule rather than the exception, and for whom, until now, we had no evidence-based options for treating insomnia. The good news is that our real-world data suggest that daridorexant may represent a valuable treatment option for a substantial proportion of patients with ADHD and insomnia disorder. Sleep should be routinely assessed in these patients, and insomnia should be treated according to the guidelines.” 

Global availability 

Daridorexant is marketed as QUVIVIQ for adult patients with insomnia by Idorsia in North America and Europe and is available in key Asia-Pacific and Middle East markets through commercial partnerships.  

Daridorexant for pediatric use is investigational and not approved or marketed in any country. 

Notes to the editor 

About daridorexant – a different kind of insomnia treatment 

Insomnia affects millions worldwide, yet commonly used treatments can lead to next day drowsiness, dependence, and withdrawal symptoms – leaving a clear unmet need for safer, effective alternatives. 

Discovered by Idorsia, daridorexant works differently from traditional hypnotics. As a dual orexin receptor antagonist, it selectively targets the orexin system, helping to regulate overactive wake signaling without broadly suppressing brain activity. Its optimized pharmacokinetics promote restorative sleep throughout the entire night, reducing morning sleepiness and improving daytime functioning. 

Clinical trials published in The Lancet Neurology demonstrated that daridorexant significantly improved sleep onset, sleep maintenance, and self-reported total sleep time in adult patients with insomnia at 25mg and 50mg doses compared to placebo. Daridorexant 50 mg also demonstrated a significant improvement in daytime functioning compared to placebo. 

About pediatric insomnia 
Pediatric insomnia is characterized by difficulty initiating or maintaining sleep that is perceived as a problem by the child or caregiver due to its severity, chronicity, frequency, and the significant daytime impairment it causes for the child or the family. 

About the pediatric Phase 2 study (NCT05423717) 

The multicenter, randomized, double-blind, placebo-controlled Phase 2 dose-finding study evaluated daridorexant 10, 25 and 50 mg, or placebo, over two weeks in 165 children and adolescents aged 10 to under 18 years with insomnia disorder. 

The primary objective of the Phase 2 study was to characterize the dose-response relationship of daridorexant on objective total sleep time (TST), using polysomnography (PSG). Patients were randomized in a 1:1:1:1 ratio to 10, 25, or 50 mg daridorexant. The primary endpoint was the change from baseline to Day 1 in TST measured by PSG. Additional assessments included objective and subjective sleep measures, sleep quality, morning sleepiness and alertness, daytime functioning, pharmacokinetics, safety and tolerability. 

The study included children and adolescents with insomnia disorder without neurodevelopmental disorders, participants with subthreshold autism spectrum disorder or attention-deficit/hyperactivity disorder traits, and participants with diagnosed neurodevelopmental disorders. 

Analysis of the primary endpoint demonstrated a statistically significant (p=0.0185) dose‑dependent improvement in TST from baseline on Day 1, accompanied by additional dose-dependent improvements across multiple objective and subjective sleep parameters. 

Importantly, the study confirmed the excellent safety and tolerability profile of daridorexant for the first time in pediatric patients as young as ten. Even at 50 mg – the recommended adult dose – daridorexant’s safety profile remained similar to placebo, with no adverse events denoting drug abuse during treatment and no indication of withdrawal symptoms upon treatment discontinuation. 

About Professor Schröder 

Carmen Schröder, MD, PhD, is Professor of Child and Adolescent Psychiatry at Strasbourg University and head of the Department of Child and Adolescent Psychiatry at Strasbourg University Hospitals in France, as well as the coordinator of the Excellence Centre for Autism and Neurodevelopmental disorders STRAS&ND and the Centre for Rare Diseases with genetic expression. Prof. Schröder’s career trajectory is international: of German origin, she has studied medicine in Germany and France, before specializing first in General Psychiatry and then in Child and Adolescent Psychiatry in France, Switzerland (Basel) and the United States (post-doctorate and junior faculty, Stanford University). She represents France since 2016 within the European Union of Medical Specialists for CAP (UEMS-CAP) and has served as its president between 2020 and 2026; she is also on the Board of Directors of the European and of the International Association of CAP (ESCAP, since 2023). 

Beyond her CAP positions, Prof. Schröder is a European ESRS Board-Certified Sleep expert and is the national coordinator of the French sleep diploma. Her main clinical and research interests (within a CNRS group at the Institute for Cellular and Integrative Neurosciences in Strasbourg) are focused on sleep and circadian rhythm disturbances in children and adolescents, in particular in neurodevelopmental disorders such as autism and ADHD. She has published more than 100 publications, mostly on implications of sleep disorders and/or circadian rhythm disorders on child’s development or child and adolescent psychiatric disorders. Prof Schröder serves as a consultant for Idorsia. 

About Dr Kunz 

Dieter Kunz, M.D., is Head of the Clinic of Sleep & Chronomedicine at St. Hedwig Hospital in Berlin, Germany, and Director of the Sleep Research and Clinical Chronobiology Research Group at Charité – Universitätsmedizin Berlin. A board-certified psychiatrist and somnologist, he has dedicated much of his career to the diagnosis and treatment of sleep disorders and to advancing research in sleep medicine and chronobiology. Dr. Kunz has served as principal investigator in numerous clinical studies and is widely recognized for his contributions to the understanding of sleep regulation and circadian biology. 

About Dr Grassi 

Giacomo Grassi, MD, PhD, is a Surgeon, specialized in Psychiatry and has a PhD in Neuroscience cum laude from the University of Florence. His clinical activity focuses on the pharmacological and non-pharmacological treatment of neuropsychiatric disorders. He deals with mood and anxiety disorders and is an expert in impulsive-compulsive spectrum disorders and attention deficit hyperactivity disorder (ADHD). He is an expert in neuromodulation therapy (transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS)) applied to treatment-resistant neuropsychiatric disorders (mood disorders, anxiety disorders, obsessive-compulsive spectrum disorders, attention deficit hyperactivity disorder, behavioral addictions). In these areas she carried out research at the Academic Medical Center of Amsterdam between 2013 and 2014 and carried out clinical and research activities at the Institute of Neuroscience in Florence from 2015 to 2019. 

Dr Grassi carries out research in the field of ADHD, obsessive-compulsive disorder and neuromodulation and is the author of numerous scientific publications in international journals (see CV). Since 2017 he has been elected a member of the board of directors of the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS, UK) of which he is still a member and in 2018 he was appointed a member of the board of directors of the Italian Academy of Behavioral Addiction Sciences (AiSdICO). He is also a member of the ADHD World Federation. For neuromodulation he is a member of the European Society for Brain Stimulation (ESBS) and the Clinical TMS Society. 

He is a member of the editorial board of the international journal Comprehensive Psychiatry and the Brazilian Journal of Psychiatry and works as a peer-reviewer of many international journals of psychiatry and neuroscience. Dr Grassi serves as a consultant for Idorsia. 

About Sleep Europe 2026 

Sleep Europe 2026, the 28th Congress of the European Sleep Research Society, will take place in Maastricht, the Netherlands, from October 20 to 23, 2026. Held every two years, the congress brings together more than 3000 clinicians, researchers, scientists and other sleep professionals to share and discuss the latest advances in sleep medicine and sleep research. 

About Idorsia 

The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. 

Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). 

For further information, please contact: 

Investor & Media Relations 

Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil 

+41 58 844 10 10 

investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com 

The above information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “intend”, “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Idorsia has transferred its rights for aprocitentan, cenerimod and selatogrel to Idorsia Investments SARL to allow the repayment of notes issued in connection with the repurchase offer completed in August 2025. More details on the transfer can be found in the current Financial Report. 

Attachment

• Press Release PDF

• Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years, without the need for chronic B-cell depletion¹˒²
• MRI disease activity significantly reduced with remibrutinib vs. teriflunomide in two trials, including reductions in T2 lesion activity by 65% and 70%, and Gd+ T1 lesions by 66% across both trials¹
• Over 92% of remibrutinib patients remained free from disease progression as assessed by 6-month CDP, showing clinically meaningful delay of nearly 30% vs. teriflunomide with nominal significance¹
• No liver safety signal observed, including no Hy’s Law cases, consistent with proven, robust safety profile of remibrutinib in chronic spontaneous urticaria and symptomatic dermographism¹˒³^–⁵

Basel, October 23, 2026 – Novartis today presented positive results from the pivotal Phase III REMODEL-1 and REMODEL-2 trials in relapsing multiple sclerosis (RMS) showing that remibrutinib, a highly selective and efficacious oral Bruton’s tyrosine kinase (BTK) inhibitor, demonstrated superior relapse control and a clinically meaningful delay in disease progression versus teriflunomide with no liver safety signal.¹˒⁶˒⁷ The study results were presented during a late-breaking session at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting, and were published simultaneously in The Lancet.¹˒⁸

“The REMODEL trial results showed that oral remibrutinib delivered a significant reduction in relapse activity while also showing a clinically meaningful effect on confirmed disability progression in people living with relapsing MS,” said Prof. Dr. Heinz Wiendl, Professor of Neurology and Chair of the Department of Neurology and Neurophysiology at the Medical Center, University of Freiburg. “As treatment goals in MS continue to evolve beyond relapse control alone, these efficacy findings, together with the favorable safety profile, suggest remibrutinib has the potential to deliver a meaningful, differentiated treatment option for people living with RMS.”

Remibrutinib reduced the annualized relapse rate (ARR) versus teriflunomide (REMODEL-1: 0.073 vs. 0.112; REMODEL-2: 0.080 vs. 0.116), the primary endpoint of both trials, with statistically significant and clinically meaningful 35.2% and 31.2% relative reduction, translating to approximately one relapse every 13 years.¹ Remibrutinib achieved a clinically meaningful delay in disability progression, reducing the risk of 6-month confirmed disability progression (6mCDP) by 29.2%, with nominal significance, and a consistent positive trend of 20.5% reduction in 3-month confirmed disability progression (3mCDP).¹ More than 92% of patients receiving remibrutinib remained free from disease progression over 24 months as assessed by 6mCDP.¹

In addition to the efficacy findings, remibrutinib demonstrated no liver safety signal, including no Hy’s Law cases, which have been reported in other late-stage BTK inhibitor programs.¹˒⁹ Across both trials, patients treated with remibrutinib experienced fewer liver enzyme elevations at every threshold, including ALT >3×ULN in 2.0% of patients versus 7.4% with teriflunomide, with the remibrutinib arm rate in range with that seen in placebo groups in prior RMS trials.¹˒⁷˒⁹^–¹³ In pooled analyses, treatment discontinuations due to adverse events (AEs) were nearly 50% fewer with remibrutinib than teriflunomide (3.1% vs. 5.8%).¹

Remibrutinib is a highly selective, covalent, oral BTK inhibitor that blocks the BTK pathway, reducing activation of B cells and innate immune cells to modulate immune regulatory networks and related neuroinflammation.⁶˒⁷ Designed to modulate BTK signaling without chronic B-cell depletion, remibrutinib represents a differentiated approach to immune regulation.²˒¹⁴ In preclinical studies, remibrutinib demonstrated the highest BTK selectivity among tested BTK inhibitors.¹⁵

“Novartis has a two-decade legacy developing therapies in multiple sclerosis and continues to advance innovation for people living with the disease,” said Shreeram Aradhye, President, Development, and Chief Medical Officer, Novartis. “The Phase III REMODEL results reinforce our confidence in remibrutinib and its potential to expand treatment choice for people living with RMS. By combining high efficacy with a favorable safety profile through a selective mechanism, remibrutinib has the potential to support long-term disease management without chronic B-cell depletion and to redefine what may be possible across the MS journey.”

Additional efficacy findings
Remibrutinib demonstrated superiority versus teriflunomide on all key secondary endpoints within each trial, including significantly reducing disease activity in the brain, as evidenced by MRI scans.¹ Compared with teriflunomide, remibrutinib significantly reduced annualized T2 lesion activity, a marker of chronic disease burden (REMODEL-1: 0.94 vs. 2.71; REMODEL-2: 0.82 vs. 2.77), and significantly reduced the rate of Gd+ T1 lesions per scan, a marker of active inflammation (REMODEL-1: 0.08 vs. 0.24; REMODEL-2: 0.07 vs. 0.21).¹ Serum neurofilament light chain (NfL) outcomes were significantly improved by 9.0% in REMODEL-1 (11.57 vs. 12.73) and 7.0% in REMODEL-2 (12.05 vs. 13.00) versus teriflunomide.¹

In the preplanned pooled REMODEL-1/2 analysis, patients receiving remibrutinib had approximately three times higher odds of achieving overall disease control versus patients receiving teriflunomide.¹ A nominally significant difference in NEDA-3 was observed, with 55.0% of patients receiving remibrutinib achieving no evidence of disease activity across three domains: relapses, disability progression and MRI activity, versus 32.1% of patients receiving teriflunomide.¹

Additional safety findings
The safety profile of remibrutinib was consistent with the broader development program.¹˒³^–⁵˒¹⁶ Numerically fewer patients receiving remibrutinib experienced AEs (79.5% vs. 81.5%) and serious AEs (6.0% vs. 7.0%) than those receiving teriflunomide.¹ Two deaths occurred in the remibrutinib group and were both assessed by investigators as unrelated to study treatment: one accidental carbon monoxide poisoning, for which suicide was ruled out, and one completed suicide.¹ 

Novartis plans to seek regulatory approval for remibrutinib in RMS globally. 

About multiple sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by myelin destruction and axonal damage in the brain, optic nerves and spinal cord.¹⁷ MS, which affects nearly 3 million people worldwide, can be characterized into three main types: non-active secondary progressive (SPMS), primary progressive (PPMS), and relapsing MS (RMS).¹⁸˒¹⁹ RMS is the most common form and includes clinically isolated syndrome (CIS), relapsing-remitting (RRMS), and active SPMS.¹⁹ The various forms of MS are distinguished by how the disease presents and progresses, including whether patients experience relapses, worsening disability over time, or a combination of both.²⁰

About remibrutinib
Discovered at Novartis, remibrutinib is being investigated in the Phase III REMODEL trials in relapsing multiple sclerosis (RMS) and Phase III REMASTER trial in secondary progressive MS (SPMS). ²¹^–²³ Remibrutinib is also being studied in other immune-mediated conditions, such as hidradenitis suppurativa and food allergy.²⁴˒²⁵ Remibrutinib 25 mg was approved for the treatment of adults with chronic spontaneous urticaria (CSU) under the brand name Rhapsido® by the FDA in September 2025 and by the European Medicines Agency in April 2026. ²⁶˒²⁷ In October 2026, Rhapsido received FDA approval as the first treatment for adults with symptomatic dermographism (SD), the most common form of chronic inducible urticaria.⁵ 

About the REMODEL trials
REMODEL-1/-2 are identical multicenter, randomized, double-blind, active comparator-controlled Phase III studies evaluating the efficacy and safety of remibrutinib compared to teriflunomide for adult patients with relapsing multiple sclerosis (RMS). Approximately 2,000 patients globally with evidence of recent disease activity and an Expanded Disability Status Scale (EDSS) of 0.0–5.5 were randomized 1:1 to receive remibrutinib 100 mg or teriflunomide. The studies consist of an initial double-blind Core Part with a flexible duration of up to a maximum of 30 months, followed by an open-label extension for up to 5 years. The primary endpoint is annualized relapse rate (ARR). Key secondary endpoints include 3- and 6-month confirmed disability progression, the number of new/enlarging T2 lesions per year, the number of Gd+ T1 lesions per scan, serum neurofilament light chain (sNfL) concentration, and the percentage of participants with no evidence of disease activity (NEDA-3).²¹˒²²˒²⁸ 

About Novartis in Neuroscience
Neurological diseases are deeply personal, affecting people of any age, from newborns to seniors, often striking in the prime of life. In multiple sclerosis (MS), Novartis has helped shape the treatment landscape for decades through scientific innovation and leadership in advancing care for people living with MS. We remain focused on addressing unmet needs and pursuing new approaches that may improve outcomes for people across the MS journey. Building on this foundation, we are doubling down on our commitment to neurology, expanding our legacy of innovation in MS and spinal muscular atrophy (SMA) to work in neuroimmunology, neurodegeneration, and neuromuscular diseases. Our goal is to protect people’s health across their lifespan, developing more treatment options that lead to better outcomes.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” or similar expressions, or by express or implied discussions regarding: potential new products; potential new indications for existing products; potential product launches or potential future revenues from any such products; results of ongoing clinical trials; or potential future, pending or announced transactions; potential future sales or earnings; strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; or our capital structure. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the success of our key products, commercial priorities and strategy; research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence, and new business models; potential significant breaches of information security or disruptions of our information technology systems; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future global exchange rates; future demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. 

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. 

Reimagine medicine with us: Visit us at www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. 

References 

Comprehensive disease control defined by Phase 3 REMODEL-1/-2 efficacy results presented at MSToronto2026 and Novartis data on file

¹Wiendl, H et al. Efficacy and safety of remibrutinib vs. teriflunomide in relapsing multiple sclerosis: results of the Phase 3 REMODEL-1/-2 trials. Presentation at: MSToronto 2026 Medical Congress; October 23, 2026; Toronto, Ontario, Canada.
²Nuesslein-Hildesheim B, Ferrero E, Schmid C, et al. Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis. J Neuroinflammation. 2023;20(1):194. Published 2023 Aug 26. doi:10.1186/s12974-023-02877-9
³Metz M, Giménez-Arnau AM, Hide M, et al. Remibrutinib in chronic spontaneous urticaria. N Engl J Med. 2025;392(10):984-994. doi:10.1056/NEJMoa2408792 
⁴Giménez-Arnau AM, Szalewski R, Hide M, et al. Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies. J Allergy Clin Immunol. 2026;157(1):143-154. doi:10.1016/j.jaci.2025.09.028 
⁵Novartis. Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU). News release. Novartis. October 7, 2026. Available from: https://www.novartis.com/news/media-releases/novartis-rhapsido-remibrutinib-receives-fda-approval-first-treatment-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu Last accessed: October 19, 2026
⁶ Angst D, Gessier F, Janser P, et al. Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. J Med Chem. 2020;63(10):5102-5118. doi:10.1021/acs.jmedchem.9b01916 
⁷Kaul M, End P, Cabanski M, et al. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clin Transl Sci. 2021;14(5):1756-1768. doi:10.1111/cts.13005 
⁸Wiendl H, Bermel R, Airas L, et al. Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials. Lancet 2026; published online Oct 23 
⁹Lambe J, Fox RJ. Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis. Drugs. 2026 Jul;86(7):989-1012. doi: 10.1007/s40265-026-02324-y. Epub 2026 May 13. PMID: 42126690; PMCID: PMC13290806
¹⁰Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910. doi:10.1056/NEJMoa044397
¹¹Maxwell CR, Turner TJ, Wallstroem E, et al. Tolebrutinib liver safety: A detailed overview. Mult Scler Relat Disord. 2026;113:107404. doi:10.1016/j.msard.2026.107404
¹²O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-1303. doi:10.1056/NEJMoa1014656
¹³Arnold DL, Elliott C, Martin EC, Hyvert Y, Tomic D, Montalban X. Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial. Neurology. 2024;102(5):e208058. doi:10.1212/WNL.0000000000208058
¹⁴Jain RW, Rayatpour A, Hagen K, et al. Investigations of remibrutinib in models pertinent to multiple sclerosis. Neurotherapeutics. 2026;23(3):e00923. doi:10.1016/j.neurot.2026.e00923 
¹⁵Pulz R, Angst D, Cenni B. Next generation Bruton’s tyrosine kinase inhibitors – characterization of in vitro potency and selectivity. Eur J Pharmacol. 2025;1002:177747. doi:10.1016/j.ejphar.2025.177747
¹⁶Novartis. Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU). Novartis US. Published February 18, 2026. Available from: https://www.novartis.com/us-en/news/media-releases/novartis-remibrutinib-first-therapy-achieve-phase-iii-primary-endpoint-chronic-inducible-urticaria-cindu Last accessed: October 19, 2026
¹⁷Ferreira HB, Neves B, Guerra IM, Moreira A, Melo T, Paiva A, Domingues MR. An overview of lipidomic analysis in different human matrices of multiple sclerosis. Mult Scler Relat Disord. 2020;44:102189. doi:10.1016/j.msard.2020.102189  
¹⁸Portaccio E, Magyari M, Kubala Havrdova E, et al. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. Lancet Reg. Health Eur. 2024;44:100977 
¹⁹National Multiple Sclerosis Society. Types of MS. Available from: https://www.nationalmssociety.org/What-is-MS/Types-of-MS Last accessed: October 19, 2026
²⁰Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-286. doi:10.1212/WNL.0000000000000560 
²¹ClinicalTrials.gov. NCT05147220. Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis (RMS) (REMODEL-1). Available from: https://clinicaltrials.gov/study/NCT05147220 Last accessed: October 19, 2026 
²²ClinicalTrials.gov. NCT05156281. Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis (RMS) (REMODEL-2). Available from: https://clinicaltrials.gov/study/NCT05156281 Last accessed: October 19, 2026 
²³ClinicalTrials.gov. NCT07225504. A study to evaluate the efficacy and safety of remibrutinib in secondary progressive multiple sclerosis (REMASTER). Available from: https://clinicaltrials.gov/study/NCT07225504 Last accessed: October 19, 2026 
²⁴ClinicalTrials.gov. NCT03827798. Study of efficacy and safety of investigational treatments in patients with moderate to severe hidradenitis suppurativa. Available from: https://clinicaltrials.gov/ct2/show/NCT03827798. Last accessed: October 19, 2026 
²⁵ClinicalTrials.gov. NCT05432388. Study of efficacy, safety and tolerability of remibrutinib in adult participants with an allergy to peanuts. Available from: https://clinicaltrials.gov/study/NCT05432388 Last accessed: October 19, 2026
²⁶Novartis. Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU). News release. Novartis. September 30, 2025. Available from: https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-rhapsido-remibrutinib-only-oral-targeted-btki-treatment-chronic-spontaneous-urticaria-csu Last accessed: October 19, 2026 
²⁷Novartis. Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria. News release. Novartis. April 27, 2026. Available from: https://www.novartis.com/news/media-releases/novartis-rhapsido-receives-european-commission-approval-first-oral-targeted-treatment-chronic-spontaneous-urticaria Last accessed: October 19, 2026 
²⁸Wiendl H, Airas L, Chitnis T, et al. Phase 3 REMODEL I/II Trials: Efficacy, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis. Mult Scler Relat Disord. 2023;80:105315. doi:10.1016/j.msard.2023.105315 
  
Novartis Media Relations
E-mail: media.relations@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com